Compare DexCom, Inc. (DXCM) vs US Bancorp (USB) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

U.S. Bancorp (USB) trades at $62.14, down 0.32% on the day, with a bullish technical outlook supported by moving averages and positive earnings momentum. The company reported record quarterly revenue in Q2 2026, beating EPS estimates, with strong loan growth and fee income driving performance. Valuation metrics show a P/E of 13.21 and P/B of 1.66, while profitability remains solid with a 27.04% net income margin and 13.24% ROE.

The outlook remains positive with analyst consensus pointing to 8% upside to the $67 price target, though risks include elevated investing cash outflows and debt levels. Recent acquisition of BTIG and new small business payment tools provide growth catalysts, while mixed technical oscillators suggest near-term consolidation potential around current levels.